Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Allena Pharmaceuticals, Inc. (ALNA)
|
Add to portfolio |
|
|
|
| Price: |
$1.25
| | Metrics |
| OS: |
122.1
|
M
| |
-1158
|
% ROE
|
| Market cap: |
$153
|
M
| |
-739
|
% ROIC
|
|
Net cash:
|
$1.68
|
M
| |
$0.01
|
per share
|
|
EV:
|
$151
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($44.7)
|
M
| |
|
|
|
EBIT
|
($44.6)
|
M
| |
|
|
| EPS |
($0.53)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative | 47.6 | 32.0 | 47.5 | | | | |
| Research and development | | | | 26.4 | 15.5 | 20.1 | 11.5 |
| General and administrative | | | | 9.2 | 5.4 | 4.1 | 2.4 |
| EBIT | -49.7 | -33.7 | -47.2 | -36.8 | -21.8 | -24.6 | -14.6 |
| Pre-tax income | -48.7 | -32.8 | -47.3 | -35.6 | -21.7 | -24.5 | -14.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -48.7 | -32.8 | -47.3 | -35.6 | -21.7 | -24.5 | -14.2 |
| |
| Diluted EPS | ($0.72) | ($1.01) | ($2.13) | ($1.72) | ($4.79) | ($18.30) | ($11.32) |
| Shares outstanding (diluted) | 68.0 | 32.5 | 22.2 | 20.7 | 4.5 | 1.3 | 1.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|